ESTECHPHARMA CO.,LTD., as one of the active pharmaceutical company, is remarkably growing more than 30% every year by concentrating all our efforts into developing new technologies by investing more than 15% of the annual turnover into R&D since our foundation in 1996. That is company ideology, challenge and creation.We've succeeded in synthesizing 40 kinds of APIs like Anti-inflammatory medicine, Anti-ulcerants, Anti-hepatitis, Treatments of Alcoholism, and etc secondly or thirdly in the world or firstly in Korea, and have been producing and supplying continuously to our customers. In present, with many patent technologies, we are co-operating new projects with domestic and world pharmaceutical companies by developing new materials new materials of Anti-hepatitis and Anti-inflammatory.In sales part, all our officers and staffs are doing wholly our best to enter the world pharmaceutical market based on domestic market's experiment.Especially, We are planning to start construction of a new plant in this year(2006) which will be complied with the cGMP rules. New construction of the cGMP plants means not only increasing of capacity but also providing facilities which fit US FDA's and world's standard. If cGMP qualified, it is estimated to accelerate our advancing in the world pharmaceutical market and it makes us to be ready to enter the world biggest market, USA. Considering only some companies are qualified cGMP in domestic market, the constructions of cGMP plant will benefit us to achieve our slogan "To be the leader of Active Pharmaceutical Ingredient". We will do our best on construction of the cGMP plant and will endeavor to be a global company with competitive power in world API market.